NASDAQ:ATYR · NASDAQ Global Market
+$0.07 today
Vol 1.48M · Avg 2.29M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Management quality matters because capital allocation choices determine how much of aTyr Pharma, Inc. earnings power becomes long-term shareholder value. Use this page to compare ATYR returns on capital, executive context, insider transactions, ownership signals, and growth trends against peers, then decide whether leadership appears disciplined, aligned, and capable of compounding through changing market conditions.
Return Metrics
ROE, ROIC & ROA over time
ROE
-109.8%
avg -75.0%
ROIC
-96.5%
avg -61.6%
ROA
-78.7%
avg -54.4%
Analysis
ROA is currently the strongest return metric at -78.7% versus its period average of -54.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sanjay S. Shukla | President, Chief Executive Officer & Director | $861,053.00 | — | 54 | $153,553.00 | 0.16% |
Jill Broadfoot | Chief Financial Officer | $596,233.00 | — | 64 | $37,296.00 | 0.04% |
Nancy E. Denyes Krueger | General Counsel & Corporate Secretary | $571,161.00 | — | 58 | $33,124.00 | 0.03% |
Peter Villiger | Vice President of Corporate Development | — | — | — | — | — |
Leslie Nangle | Vice President of Research | — | — | — | — | — |
Ashlee Dunston | Director of Investor Relations & Corporate Communications | — | — | — | — | — |
Dalia R. Rayes | Head of Commercial, Global Efzofitimod Franchise | — | — | — | — | — |
Danielle Campbell | Vice President of Human Resource | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$961,431.16
Sells
3
$6,267.01
Net Sentiment
+$955,164.15
Net buying
Most Active
SCHIMMEL PAUL
3 transactions
Analysis
Insiders reported 3 buys worth $961,431.16 and 3 sells worth $6,267.01 over the last 12 months. That adds up to net buying of $955,164.15. SCHIMMEL PAUL was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$496.47M
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$236.83M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$172.36M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$92.61M
Precision BioSciences, Inc.
NASDAQ:DTIL
$89.16M
MindWalk Holdings Corp.
NASDAQ:HYFT
$69.60M
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
$51.44M
Who manages ATYR?
aTyr Pharma, Inc. (ATYR) lists 8 active executives. The top listed executive is Peter Villiger, Vice President of Corporate Development.
Are ATYR insiders buying or selling?
Recent insider activity shows net buying of $7.65M.
Explore More
Continue the stock analysis
Jump to another research area for this company.